Skip to main content
. 2019 Nov 20;11(12):1821. doi: 10.3390/cancers11121821

Figure 3.

Figure 3

An overview of the available LSD1 inhibitors under clinical evaluation (data retrieved from [122,123] and tranylcypromine [124], ORY-1001 [89], GSK2879552 [125], and SP-2557 [126]).